Marge Simpson Research Papers

1530 Words7 Pages
Marge Simpson was born in 1979. In 2007 she found a lump in her left breast. She went to the hospital for a check up where she was diagnosed with left breast invasive ductal carcinoma stage 3 (T1,N2,M0), ER positive, HER2 negative. For the diagnosis of breast cancer it is necessary to start with a breast examination and mammography to screen for malignancies. Tissue biopsy is the definitive method and sentinel lymph node biopsy is a critical step in staging and treatment in breast cancer. CT, MRI, PET/CT are other techniques to obtain images to clarify the cancer and the future treatment. Blood test with tumour markers as CEA, CA 15-3 and CA 27-29 is also necessary. The presence of the steroid receptor, estrogen (ER), in the tissue…show more content…
The latest age-standardised relative survival for breast cancer in England during 2005-2009, shows that 95.8% of women are expected to survive their disease for at least one year, falling to 85.1% survival rate for five years or more. Genetic and lifestyle factors affect the risk of cancer and so the risk for every individual is different. Breast cancer is related to a number of exposures including tobacco, alcohol, infections, radiation, occupational exposures, and medications. Numerous studies have evaluated the risk associated with the use of oral contraceptives. It is also related with the lifestyle (diet, overweight and obesity, and physical exercise) Cancer can be related to genetics. The reasons for breast cancer clustering in families remain largely unclear, but a small proportion of families share breast cancer predisposition genes BRCA1 and BRCA2 mutations confer a high risk of breast cancer in carriers. Marge had a left modified radical mastectomy with immediate reconstruction, chemotherapy, radiotherapy. Focusing on the chemotherapy treatment, Marge was commenced on…show more content…
A discussion of interventions should include both inverventions found to be effective in the prevention of neutropenia as well as those used for the treatment of confirmed neutropenia. With pharmacologic interventions we can find the hematopoietic growth factors. (HGFs) are used to reduce the period of neutropenia, which is the highest period of risk for infection. These glycoproteins activate the production and maturation of specific cell lines. Granulocyte colony stimulating factor (G-CSF) prompts neutrophil growth, whereas granulocyte-macrophage colny-stimulating factor (GM-CSF) stimulates both neutrophils and macrophages. The use of growth factors as a method to prevent infection has been well established. Until 2003, filgrastin (Neupogen) was the G-CSF that was primarily used for prevention of chemotherapy-induced neutropenia. In 2003 there was release of a pegylated, longer acting formulation of G-CSF, pegfilgrastim (Neulasta). The once-per-cycle pegfilgrastim may allow for better adherence to the recommended dosing schedule as compared to filgrastim, which requires daily

More about Marge Simpson Research Papers

Open Document